commerci present signific
polit headwind drug price drug may
fail clinic gain regulatori approv
compani may requir addit financ
top pick therapeut
recent gain cabometyx approv kidney cancer almost
month ahead februari pdufa date file snda
liver cancer partner roch could report phase cotezo
data microsatellit stabl colorect cancer msscrc report
proof-of-concept bispecif antibodi data dramat expand pipelin
bispecif antibodi clinic last least report first-
in-man solid tumor data well file ind ipsc-deriv natur
killer nk cell therapi focu name
acceleron tetraphas ttph aveo oncolog aveo
ow pt look continu grow cabometyx
recent renal cell carcinoma rcc approv increas sale
forecast million report full phase celesti data
cabometyx liver cancer asco-gi januari file snda quarter
approv like importantli partner roch report phase cotezo
data cotel plu atezolizumab microsatellit stabl colorect
cancer conduct two phase trial metastat melanoma
ow pt expand bispecif antibodi clinic
includ novartis-partn bispecif
aml b-cell malign current phase studi
preliminari data year novarti licens ex-u right million up-front
bispecif preclin candid third clinic start expect
phase neuroendocrin gist tumor studi
yet expect file ind
xencor plan begin
phase trial subcu diseas
ow pt develop cellular immunotherapi cancer immun
diseas allogen natur killer nk cell therapi recent
show first morpholog leukemia-fre state mlf phase voyag studi
aml report first-ev solid tumor data phase
dimens apollo studi importantli develop pipelin
ipsc-deriv cell therapi could enter clinic year
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
ow pt remain confid tezacaftor/ivacaftor approv homozyg
residu function patient februari pdufa date project
exist orkambi new homozyg function patient transit
start tez/iva gate mutat patient remain kalydeco forecast
total cf sale grow billion top-lin drive earn growth
non-gaap dilut ep year importantli vertex least one year ahead
competit plan phase trial start two triplerx regimen homozyg
heterozyg patient earli year ultim anticip patient
consolid onto triplerx vertex host analyst event next monday januari
pt san francisco
ow pt alnylam could gain first-ev rnai drug approv patisiran
hereditari attr amyloidosi europ follow-on subcu
begin phase trial year alnylam report interim phase
envis data wholly-own givosiran acut intermitt porphyria enabl
nda file alnylam drug approv partner front
medicin compani mdco cover recent initi first phase orion trial
rnai inclisiran fda lift clinic hold fitusiran enabl three phase
atla trial hemophilia resum alnylam host analyst event next wednesday
januari pt san francisco
data myasthenia gravi mg show statist signific mg-adl score
improv patient vs placebo patient argenx intend
meet fda discuss singl phase trial start believ
data valid efgartigimod mechan target fcrn lower auto-antibodi treat
broad rang autoimmun diseas await phase ii immun thrombocytopenia itp
pemphigu vulgari pv data argenx also report first acut
myeloid leukemia aml patient phase i/ii studi respond vidaza
look updat program continu drive valu
arri ow pt expect array transit commerci stage compani
binimetinib encorafenib approv braf-mut melanoma june
pdufa data expect uptak billion market base compar efficaci
differenti toler current approv combin preliminari braf-mut
data impress esmo phase beacon trial complet enrol next
year data like array also evalu binimetinib combin merck
bristol-my squibb recent also see upsid
array wholly-own oral inhibitor phase ii solid tumor studi
ow pt primari driver acceleron remain top-lin phase medalist
data myelodysplast syndrom md believ data transfusion-depend beta-
thalassemia celgene-partn luspatercept phase command trial
initi esa-nav lower-risk md acceleron neuromuscular franchis advanc
two phase ii studi facioscapulohumer muscular dystrophi fshd
charcot-marie-tooth cmt diseas data expect year acceleron also initi
phase ii studi sotatercept pulmonari arteri hypertens pah
ttph ow pt tetraphas develop eravacyclin treat multi-drug resist gram-
neg bacteri infect submiss valid tetraphas file
ind eravacyclin complic intra abdomin infect ciai approv earli
tetraphas report top-lin phase data eravacyclin complic
urinari tract infect cuti tetraphas also plan initi phase ii studi
oral eravacyclin
page
aveo ow pt primari driver remain top-lin phase data fotivda
tivozanib renal cell carcinoma rcc conserv expect
line approv file respons prior could lead approv advanc
rcc patient partner eusa launch fotivda germani treat first-lin metastat rcc
per cours treatment see favor econom aveo elig
royalti european sale project total fotivda european sale
million million follow impress earli respons data phase
ii tinivo studi fotivda plu opdivo random rcc patient data
page
